PROCEPT BioRobotics Pivots: Record Growth Meets Strategic Financial Reset

SAN JOSE, CA – February 25, 2026 – PROCEPT BioRobotics delivered a complex and telling financial report today, revealing a company at a strategic crossroads. While the surgical robotics firm celebrated its highest-ever quarterly procedure volume for its Aquablation therapy, the news was coupled with a significant revenue shortfall and a downward revision of its 2026 financial guidance, triggering a sharp negative reaction from investors.

The fourth-quarter 2025 results present a tale of two diverging narratives. Operationally, the company is thriving. U.S. procedures using its robotic system for benign prostatic hyperplasia (BPH) surged by an impressive 69% year-over-year to approximately 12,200. The company also sold a record 65 new systems, expanding its U.S. installed base by 42% over the prior year to 718 units. Yet, these strong adoption metrics were overshadowed by financial figures that fell short of Wall Street expectations. Total revenue for the quarter was $76.4 million, missing analyst consensus which hovered between $93 million and $96 million. More pointedly, the company reset its full-year 2026 revenue guidance to a range of $390 million to $410 million, a notable reduction from prior guidance and analyst expectations that were north of $420 million.

In a move it describes as essential for its next phase of growth, PROCEPT is deliberately pumping the brakes on certain short-term revenue drivers to build a more sustainable and profitable foundation. The resulting stock plunge, with shares plummeting nearly 27% after the announcement, underscores the market's immediate anxiety over this self-described “reset.”

A Disciplined Pivot for Long-Term Health

Company leadership attributed the fourth-quarter revenue miss and guidance adjustment to a series of deliberate strategic decisions designed to prioritize long-term financial health over short-term sales figures. The most significant of these is a new, more disciplined pricing strategy for its disposable handpieces, a key recurring revenue stream.

“We successfully reduced field inventory levels and eliminated end-of-quarter purchasing incentives,” CEO Larry Wood stated in the press release. This shift away from encouraging bulk, discounted purchases at the end of a quarter led directly to a fourth-quarter revenue shortfall but had the intended effect of boosting the handpiece average selling price (ASP) by approximately 5% sequentially to $3,340. The company now forecasts an ASP of $3,500 in 2026, expecting future handpiece sales to align more closely with actual procedure volumes rather than exceeding them.

This strategic change was compounded by a one-time cost associated with a voluntary field action during the quarter, which pressured the gross margin. Management noted the issue, related to a handpiece-system compatibility problem with no patient safety implications, was resolved and contained within the quarter. Further contributing to the short-term disruption is a major realignment of its commercial organization. The company has integrated its sales and clinical teams under a unified regional leadership structure and created a dedicated launch team of top performers to standardize and accelerate the activation of new systems. While internal pilot programs suggest this new structure can cut the time to a new system’s first 10 cases by half, the company acknowledges the reorganization will cause near-term disruption.

“We believe these actions are essential to our long-term goals of sustained high growth and establishing a favorable financial profile,” Wood explained, framing the moves as a necessary trade-off.

Aquablation's Growing Dominance in BPH Treatment

Despite the financial recalibration, the underlying story of PROCEPT BioRobotics remains one of rapid technological adoption. The impressive 69% year-over-year growth in U.S. procedures demonstrates a powerful trend: urologists and patients are increasingly choosing Aquablation therapy for BPH, a condition affecting an estimated 40 million men in the U.S. alone.

Aquablation therapy, delivered by the company’s AI-powered HYDROS Robotic System, uses a heat-free, high-pressure waterjet to remove prostate tissue. This approach is backed by a growing body of over 150 peer-reviewed publications that support its ability to provide effective and durable relief from BPH symptoms, regardless of prostate size or shape, while minimizing side effects common to other treatments.

The consistent growth in system placements and procedure volume places PROCEPT in a strong position within the competitive urological device market. As robotics become more entrenched in urology—with competitors like Intuitive Surgical dominating other prostate procedures—PROCEPT’s focused success in the BPH niche gives it a formidable foothold. The company's ability to continue this procedure growth trajectory, projected at 39% to 48% for 2026, will be the ultimate test of its strategy. The core belief is that as more surgeons use the technology and experience its benefits, utilization will deepen, driving a steady and more predictable stream of high-margin handpiece sales.

Doubling Down on Innovation: The Prostate Cancer Frontier

While implementing commercial discipline, PROCEPT is simultaneously making significant investments in its future. A key driver of the company's increased operating expenses—which rose to $77.4 million in the fourth quarter—is its funding for the ambitious WATER IV clinical trial. This global study is evaluating the use of Aquablation therapy for the treatment of localized prostate cancer.

This move represents a potential quantum leap for the company. The FDA has already granted the therapy a Breakthrough Device Designation for this indication, expediting its review process. The trial, which compares Aquablation against the current standard of care, radical prostatectomy, seeks to prove that the technology can be a safer and equally effective option for cancer treatment. Success in this trial could unlock an entirely new market for PROCEPT, which analysts estimate could be worth an additional $500 million.

This investment highlights the classic balancing act for a high-growth MedTech company: managing the path to profitability for its current commercial products while simultaneously funding capital-intensive research and development for its next blockbuster application. The WATER IV trial represents a high-risk, high-reward bet that could redefine PROCEPT BioRobotics' future and significantly expand its impact on urological care. For now, it contributes to a widening net loss, which reached $29.8 million in the fourth quarter, up from $18.9 million in the prior-year period. The company is guiding for an adjusted EBITDA loss between $17 million and $30 million for 2026, but projects it will achieve positive adjusted EBITDA by the fourth quarter of 2026, signaling that the current strategic pain is expected to yield tangible financial gains within the year.